Elsevier

Brain Research

Volume 809, Issue 1, 26 October 1998, Pages 1-4
Brain Research

Research report
Inhibition of hippocampal acetylcholine release after acute and repeated Δ9-tetrahydrocannabinol in rats

https://doi.org/10.1016/S0006-8993(98)00738-0Get rights and content

Abstract

The effects of acute and repeated administration of Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive principle of marijuana, on acetylcholine release in the hippocampus was studied in freely moving rats by microdialysis. The acute intraperitoneal (i.p.) administration of Δ9-THC at the doses of 2.5 and 5 mg/kg reduced acetylcholine release by about 25% and 45%, respectively. A dose of 7.5 mg/kg produced no further reduction. Δ9-THC effects were antagonized by the cannabinoid CB1 antagonist SR141716A at the i.p. dose of 1 mg/kg, per se ineffective in modifying acetylcholine concentrations. After a repeated exposure (twice daily for up to seven days) to Δ9-THC (7.5 mg/kg, i.p.) or vehicle (0.3 ml/kg, i.p.), the inhibitory effect of Δ9-THC (2.5 and 5 mg/kg, i.p) on acetylcholine release was not reduced. The results confirm previous observations that cannabinoids inhibit acetylcholine release through cannabinoid CB1 receptors, and indicate that no tolerance to this effects develops after a repeated Δ9-THC administration.

Introduction

Δ9-Tetrahydrocannabinol (Δ9-THC), the psychoactive principle of marijuana, is known to produce impairment in learning and memory both in humans and laboratory animals 3, 4, 8, 13, 14, 16, 18. Impairment of memory processes is also produced by the synthetic cannabinoid CB1 agonists, WIN 55,212-2 {R-(+)-(2,3-dihydro-5-methyl-3-[{4-morpholinylmethyl] pyrol [1,2,3-de]1,4-benzoxazin-6-yl) (l-naphthalenyl) methanone monomethanesulfonate} and CP 55,940 {[1a,2-(r)-5-(1,1-dimethylpheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-phenol} 18, 24and by the endogenous cannabinoid agonists, anandamide [20]and 2-AG (sn-2 arachidonylglycerol) [23]. The negative effects of the cannabinoid agonists are blocked by the cannabinoid CB1 antagonist SR 141716A, a compound that is per se able to improve memory processes in rodents 3, 24. These results indicate that the impairment in memory by Δ9-THC is mediated via CB1 receptors 19, 24and also suggest that endogenous cannabinoids play a role in cognitive processes 20, 23. Moreover, experimental evidence suggests that inhibition of cholinergic neurotransmission in the hippocampus plays an important role in cognitive alterations produced by cannabinoids [21]. Thus, cannabinoid agonists impair working memory after intrahippocampal administration [18]and inhibit long-term potentiation in hippocampal slices [5], a classic electrophysiological model for the study of learning and memory processes [1]. In addition, cannabinoid agonists reduce acetylcholine output in the hippocampus in freely moving rats [10]and [14C] acetylcholine release in hippocampal slices 11, 12.

The present study, using microdialysis techniques in freely moving rats, was carried out to determine whether the suppressant effect of Δ9-THC on hippocampal acetylcholine release would be modified by a repeated exposure to the drug. This problem is clinically relevant since chronic marijuana use has been claimed to produce persistent adverse effects on cognition 4, 16.

Section snippets

Animals

Male Sprague–Dawley rats (225–250 g; Charles River, Calco, Lecco, Italy) were housed in groups of three per cage for at least ten days before use. Food and water were freely available and animals were maintained under an artificial 12-h/12-h light/dark cycle (lights were on from 0700 to 1900). Experiments were carried out between 0800 and 1700 h.

Microdialysis implantation and experimental procedure

Rats were anesthetised with equitensin (4 mg/kg, i.p.) and dialysis tubes (AN 69-HF, with a wet fiber outer diameter of 320 μm; Hospal-Dasco, Bologna,

Effects of a single Δ9-THC administration on hippocampal acetylcholine output

As shown in Fig. 1 the administration of Δ9-THC at the dose of 2.5, and 5 mg/kg inhibited acetylcholine release by about 25% (ANOVA main effect F1,8=3.81; post-hoc P>0.05; ANOVA main effect of repeated measures F8,36=1.37; post-hoc P>0.05) and 45% (ANOVA main effect F1,8=12.17; post-hoc P<0.05; ANOVA main effect of repeated measures F8,36=4.96; post-hoc P<0.05), respectively (Fig. 1). A higher dose of 7.5 mg/kg produced no further reduction (ANOVA main effect F1,8=5.55; post-hoc P<0.05; ANOVA

Discussion

This study confirms previous observations showing that different cannabinoid agonists inhibit acetylcholine release in the hippocampus in vivo [10]as well as in hippocampal slices 5, 11and that this effect is prevented by the CB1 receptor antagonist SR141716A. Moreover, this study shows that the inhibitory effects of Δ9-THC develops after a long delay and is a lasting response: acetylcholine concentrations were reduced about 2 h after treatment and the reduction persisted for over 3 h. The

References (25)

  • J.C. Day et al.

    Dopaminergic regulation of septohippocampal cholinergic neurons

    J. Neurochem.

    (1994)
  • S. Evans

    Effects of drug abuse on acquisition of behavioural chain in squirrel monkeys

    Psychopharmacology

    (1992)
  • Cited by (0)

    View full text